Shift expands to North America to drive cell rejuvenation research

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Biotech establishing a Toronto-based team to advance the discovery of rejuvenation gene targets through AI-powered virtual cell technology.

Shift Bioscience, a biotech firm specializing in AI-driven virtual cell technology to combat age-related diseases, has announced the establishment of a new team and facilities in Toronto, Canada. This strategic expansion aims to accelerate the development of the company’s platform dedicated to identifying rejuvenation gene targets, and the Toronto team will be led by the Head of Machine Learning, Lucas Camillo, with Professor Bo Wang of the University of Toronto appointed as Senior Advisor.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2404

Shift Bioscience

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Shift Bioscience is a biotechnology company headquartered in Cambridge, United Kingdom, focused on developing therapeutics that target the underlying mechanisms of cellular aging. The company employs an AI-powered virtual cell platform combined with proprietary epigenetic aging clocks to identify and validate gene targets for cell rejuvenation across multiple age-driven diseases. Its pipeline includes SB101, an anti-fibrotic siRNA therapeutic for liver fibrosis and systemic sclerosis, and SB000, a gene therapy candidate for age-related sensory loss. Through its CLOCKWORK discovery platform, Shift aims to deliver the first drug pipeline validated for cellular age reversal in humans, addressing the root causes of aging-related morbidity and mortality.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE